Genomic Health, Inc. (GHDX) Stock Rating Reaffirmed by Jefferies Group LLC
Genomic Health, Inc. (NASDAQ:GHDX)‘s stock had its “hold” rating reiterated by research analysts at Jefferies Group LLC in a report released on Wednesday. They presently have a $33.00 target price on the medical research company’s stock, up from their prior target price of $29.00. Jefferies Group LLC’s price objective indicates a potential upside of 10.04% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the stock. Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of Genomic Health in a research note on Wednesday, May 3rd. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th. Deutsche Bank AG reaffirmed a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research note on Wednesday, January 18th. TheStreet raised shares of Genomic Health from a “d+” rating to a “c-” rating in a research note on Monday, February 27th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 price target on shares of Genomic Health in a research note on Tuesday, January 17th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $32.00.
Shares of Genomic Health (NASDAQ:GHDX) traded down 8.68% during trading on Wednesday, hitting $29.99. 261,919 shares of the company were exchanged. The stock’s market cap is $1.02 billion. The company’s 50-day moving average price is $31.73 and its 200 day moving average price is $30.40. Genomic Health has a 12 month low of $23.57 and a 12 month high of $33.96.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, May 9th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Genomic Health had a negative return on equity of 14.13% and a negative net margin of 5.77%. The firm had revenue of $84 million for the quarter, compared to analysts’ expectations of $86.21 million. During the same period last year, the firm earned ($0.19) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities analysts predict that Genomic Health will post $0.02 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/05/10/genomic-health-inc-ghdx-stock-rating-reaffirmed-by-jefferies-group-llc.html.
In other news, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $31.09, for a total value of $155,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laura Leber sold 3,072 shares of Genomic Health stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $31.88, for a total transaction of $97,935.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,567 shares of company stock valued at $957,410. 47.00% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Russell Investments Group Ltd. acquired a new position in Genomic Health during the fourth quarter valued at approximately $575,000. Dubuque Bank & Trust Co. acquired a new position in Genomic Health during the first quarter valued at approximately $142,000. Norges Bank acquired a new position in Genomic Health during the fourth quarter valued at approximately $4,546,000. Motley Fool Wealth Management LLC raised its position in Genomic Health by 3.2% in the fourth quarter. Motley Fool Wealth Management LLC now owns 123,139 shares of the medical research company’s stock valued at $3,619,000 after buying an additional 3,812 shares during the period. Finally, Bogle Investment Management L P DE raised its position in Genomic Health by 46.0% in the fourth quarter. Bogle Investment Management L P DE now owns 103,262 shares of the medical research company’s stock valued at $3,034,000 after buying an additional 32,554 shares during the period. 89.50% of the stock is owned by institutional investors and hedge funds.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.